Li-Chung Tsao

Development of a STEAP1-targeted prostate cancer specific antibody drug conjugate platform with immunostimulatory properties

Background: Patients with prostate cancer who develop androgen pathway modulation resistant (APMR) disease face lethal outcomes despite advances in androgen receptor-pathway inhibitors, chemotherapy, and PSMA-directed radioligands. Antibody-drug conjugates (ADCs) have demonstrate...

Activation of FcγR and classical complement pathways contribute to T-DXd plus pertuzumab therapeutic efficacy

In addition to delivering cytotoxic payloads, HER2-targeted antibody–drug conjugates (ADCs) can engage innate immune effector pathways (such as FcγR and complement) similar to monoclonal antibodies (mAbs). However, the relative contribution of innate pathways to therapeutic benef...